相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
Lene Nygaard Axelsen et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Selexipag for the treatment of pulmonary arterial hypertension
Leon Genecand et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2021)
Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
Hans Klose et al.
RESPIRATORY RESEARCH (2021)
Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method
Saili Xie et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2020)
Cross-species comparison of the metabolism and excretion of selexipag
Tomohiko Ichikawa et al.
XENOBIOTICA (2019)
Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro
Shunji Imai et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Effect of Dietary Doses of Quercetin on Hepatic Drug Metabolizing Enzymes in Spontaneously Hypertensive Rats
Fawzy Elbarbry et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2019)
Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag
H. Klose et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2019)
Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans
Wijdan M. Dabeek et al.
NUTRIENTS (2019)
New treatment options for pulmonary arterial hypertension — the first selective IP-receptor agonist selexipag
N. V. Ilyin et al.
CARDIOVASCULAR THERAPY AND PREVENTION (2019)
Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension
Onur Yazici et al.
MEANDROS MEDICAL AND DENTAL JOURNAL (2019)
Baseline history of patients using selexipag for pulmonary arterial hypertension
Kristin B. Highland et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2019)
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag
Carmela Gnerre et al.
XENOBIOTICA (2018)
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension
Shirin Bruderer et al.
EXPERT OPINION ON DRUG SAFETY (2017)
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential
John Gatfield et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies
Lei Cao et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2017)
Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects
Shirin Bruderer et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment
Priska Kaufmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension
Mayank Sardana et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
Priska Kaufmann et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2015)
Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects
Priska Kaufmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
Tetsuo Asaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8)
Chia Yong Pang et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects
KA Kim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Prostanoid therapy for pulmonary arterial hypertension
DB Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes
D Projean et al.
XENOBIOTICA (2003)
分享论文
